Abstract:Background Telomerase reverse transcriptase promoter (pTERT) mutation status plays a key role in the decision-making and prognosis prediction of glioblastoma (GBM). The purpose of this study was to assess the prediction value of diffusion-weighted imaging (DWI) in the pTERT mutation status of GBM Methods MR imaging data and molecular information of 266 patients with GBM were obtained from the Second Affiliated Hospital of Zhejiang University (n=266). We trained the same residual convolutional neural network (ResNet) for each MR modality, including structural MRIs (T1-weighted, T2-weighted, contrast enhanced T1-weighted) and DWI and its associated ADC map, and their combinations to compare the predictive capacities between DWI and conventional structural MRI. Moreover, we explored the effect of different Region of interests (ROIs) on the outcome of pTERT mutation status prediction: entire tumor (solid tumor, edema and cystic regions), tumor core (solid tumor), and enhanced tumor. Results Structural MRI modalities and their combination performed poorly in predicting the pTERT mutation status (accuracy, 51-54%, AUC, 0.545-0.571), while DWI in combination with its ADC maps yielded the best predictive performance (accuracy = 85.2%, AUC= 0.934). The further including of radiological and clinical characteristics could not further improve the predictive performance of pTERT mutation status. Among the three ROI selections, the entire tumor volume yielded the best prediction performance. Conclusion DWI and its associated ADC maps shows promising prediction value in the pTERT mutation in GBM and are suggested to be included into the MRI protocol of GBM in clinical practice. Key Points ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The whole work was supported by grants from the National Natural Science Foundation of China (81502139). Clinical Research Center for Neurological Diseases of Zhejiang Province(2021E50006). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee of the Second Affiliated Hospital of Zhejiang University School of Medicine gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors

Predicting telomerase reverse transcriptase promoter mutation in glioma: A systematic review and diagnostic meta-analysis on machine learning algorithms

Multi-parameter MRI Based Radiomics Nomogram for Predicting Telomerase Reverse Transcriptase Promoter Mutation and Prognosis in Glioblastoma.

Prediction of TERT mutation status in gliomas using conventional MRI radiogenomic features

MRI radiomics model for predicting TERT promoter mutation status in glioblastoma

Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas

Association of human telomerase reverse transcriptase promoter mutation with unfavorable prognosis in glioma: A systematic review and meta-analysis

Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI

Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis

Radiomics-Based Prediction of TERT Promotor Mutations in Intracranial High-Grade Meningiomas

A radiomics‐based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma

Diagnostic Performance of Deep Learning for Predicting Gliomas' IDH and 1p/19q Status in MRI: A Systematic Review and Meta-Analysis

Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O6 -methylguanine-DNA methyltransferase promoter methylation in patients with gliomas

Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria

MGMT promoter methylation status prediction using MRI scans? An extensive experimental evaluation of deep learning models

Prediction of the Molecular Subtype of IDH Mutation Combined with MGMT Promoter Methylation in Gliomas via Radiomics Based on Preoperative MRI

Machine Learning and Glioblastoma: Treatment Response Monitoring Biomarkers in 2021

TERT Gene Mutation in Gliomas Cross‐Linked With (NTRK, PDL1, ALK, IDH, P53, EGFR, HER2): A Integrative Review TERT Gene Mutation in Gliomas

Assessing Metabolic Markers in Glioblastoma Using Machine Learning: A Systematic Review

Diffusion Weighted MRI could precisely predict the pTERT mutation status of GBM using a residual convolutional neural network

Diffusion-weighted MRI precisely predicts telomerase reverse transcriptase promoter mutation status in World Health Organization grade IV gliomas using a residual convolutional neural network

TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas